MedWatch

Sunstone company receives milestone from Janssen

The Swedish biotech company Alligator Biosciences is to initiate a new clinical study with an immune activating antibody and it triggers a milestone of USD 6 million from the partner Janssen.

Foto: Janssen PR

Johnson & Johnson’s subsidiary Janssen has sent a million-dollar check to Swedish Alligator Biosciences, the company behind the cancer candidate ADC-1013.

Alligator Biosciences licensed the drug to Janssen in 2015 and the deal can potentially bring the Swedish company nearly USD 700 million. Currently, the partnership resulted in the first milestone as ADC-1013 now is ready for a clinical combination study with one of Janssen’s proprietary PD-1 inhibitors.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier